⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRBP News
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
globenewswire.com
CRBP
EDGE Markets Partners with Splash Sports to Bring 24/7 Banking to the $21 Million NFL Survivor Contest
prnewswire.com
CRBP
Ric Burns' Acclaimed NEW YORK: A DOCUMENTARY FILM Returns with Two New Films September 21st and 22nd On PBS
prnewswire.com
AMX
GOOG
CMCSA
IBM
MSFT
NVDA
INTC
META
AMZN
NFLX
ABNB
UBER
LYFT
TSLA
GM
F
RIVN
NIO
XPEV
LI
PLTR
SNOW
CRM
ADBE
GOOGL
MSCI
SPGI
BKNG
EXPE
MAR
H
WYNN
LVS
MGM
CHTR
VZ
T
QCOM
AMD
MU
AMAT
ASML
TXN
NXPI
ON
ADI
LRCX
KLAC
MRVL
WDC
SE
BABA
JD
PDD
BIDU
BILI
IQ
VIPS
HTHT
NTES
EDU
BEKE
RMAX
Z
HOFT
PG
KO
PEP
MCD
SBUX
YUM
CMG
WEN
CAKE
BJRI
EAT
DRI
BLMN
TH
QSR
SONO
BBY
WMT
TGT
HD
LOW
COST
TJX
ROST
M
KSS
URBN
ANF
AEO
LULU
NKE
UA
CROX
RL
PVH
TPR
CPRI
KHC
GIS
CL
EL
ORCL
SAP
ACN
HPQ
DELL
CSCO
INTU
PYPL
AXP
V
MA
JPM
BAC
WFC
C
MS
GS
SCHW
RJF
LPLA
BEN
IVZ
AB
PGR
ALL
TRV
CB
UNM
MET
PRU
AIG
LNC
GL
CCI
AMT
EQIX
DLR
COR
NTAP
STX
WD
CDNS
SNPS
QTRX
REGN
GILD
AMGN
BMY
ABBV
LLY
PFE
MRK
JNJ
BIIB
VRTX
ALKS
AZN
SNY
NVS
CRSP
EDIT
NTLA
BNTX
MRNA
EXAS
ILMN
ROKU
CRWD
COIN
MARA
RIOT
FTFT
BTBT
CLSK
HUT
GLXY
NNDM
IONQ
RIG
NVCR
CRBU
ACRS
APLS
AXSM
CLDX
CRBP
CUE
CYTK
DASH
GRWG
PLUG
FCEL
BE
NEE
DUK
SO
EXC
SRE
PCG
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRBP
Form 8-K
sec.gov
CRBP
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
globenewswire.com
CRBP
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
globenewswire.com
CRBP
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
globenewswire.com
CRBP
GoodLeap Introduces the GoodLeap Home Visa Signature® Card with 6% Cash Back¹ on Home Project, the Highest Rate Available for Home Improvement Spending
prnewswire.com
CRBP
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
globenewswire.com
CRBP